To improve the detection efficiency of the three methodologies, we investigated if combining the clinicopathological characteristics of NSCLC with the EML4-ALK fusion gene would yield useful information for the effective pre-screening of patients with the EML4-ALK fusion gene in clinical practice. This evidence concerns the gene ALK and non-small cell lung carcinoma.